Table 3.
Apheresis information and adjunctive therapy.
| Total patients (n = 301) | n (% of whom information available) | |
|---|---|---|
| Information available N (% ofTotal) | ||
| Fluid replacementa | 175 (58.1) | |
| Plasma | 131 (74.9) | |
| Albumin | 45 (25.7) | |
| Peripheresis anticoagulanta |
173 (57.5) | |
| Citrate | 73 (42.2) | |
| Heparin | 101 (58.4) | |
| Timing (Hours)b | 117 (38.9) | |
| <24 | 26 (35.6) | |
| 24–48 | 25 (34.2) | |
| 48–72 | 12 (16.4) | |
| >72 | 10 (13.7) | |
| No. sessions | 231 (76.7) | |
| 1 | 149 (62.2) | |
| 2 | 46 (19.9) | |
| 3 | 18 (7.8) | |
| >3 | 18 (7.8) | |
| Adjunct therapy | 85 (28.2) | |
| IV Insulin | 35 (41.2) | |
| IV Heparin | 13 (15.3) | |
| Fibrate | 28 (32.9) | |
| Niacin | 4 (4.7) | |
| Statin | 3 (3.5) | |
| Nafamostat mesilate |
2 (2.4) |
IV: intravenous.
a
The predominant fluid or anticoagulant was recorded. One patient received plasma and albumin in equal proportion and one patient received anticoagulation with citrate and heparin in equal amounts.
b
73 patients had individual timing information available. 44 patients from case series were reported as cumulative timing.